Incyte (INCY) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Incyte (INCY) Misses Q1 EPS by 2c

Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs

May 1, 2018 7:00 AM EDT

Total product-related revenues of $382 million in Q1 2018, representing 30 percent growth over the same period last year; Jakafi® (ruxolitinib) revenues of $314 million in Q1 2018, representing 25 percent growth over the same period last year FDA Advisory Committee recommended approval of baricitinib 2mg for the treatment of moderately-to-severely active rheumatoid arthritis Management to highlight corporate growth and development portfolio in oncology and other indications at investor and analyst event on June 21, 2018

First-Quarter Conference Call and Webcast Scheduled Today at 8:00 a.m. ET

WILMINGTON,... More